Healthcare
Aurenar
Recorded July 22, 2025
Aurenar has developed a non-invasive device that boosts the body’s natural control of inflammation, improving ICU outcomes and lowering costs.
Aurenar has developed a non-invasive device that boosts the body’s natural control of inflammation, improving ICU outcomes and lowering costs.
A biopharmaceutical company developing the first hormone-free, topical treatment for Vulvovaginal Atrophy (VVA)
A biopharmaceutical company developing the first hormone-free, topical treatment for Vulvovaginal Atrophy (VVA)
Serina Therapeutics (NYSE: SER) is pioneering drug optimization technologies to redefine the standard of care in advanced Parkinson’s and other diseases
Serina Therapeutics (NYSE: SER) is pioneering drug optimization technologies to redefine the standard of care in advanced Parkinson’s and other diseases
Regenxbio [NASDAQ: RGNX] has three assets in pivotal trials with the potential to become standard of care in markets worth a total of $26B.
AcuamarkDX has developed a blood-based cancer detection platform for all stage 1 and 2 cancers where survival rates are highest.
AcuamarkDX has developed a blood-based cancer detection platform for all stage 1 and 2 cancers where survival rates are highest.
Adora Life Science is unlocking the potential of a drug that can slow the progression of degenerative joint disease.
Adora Life Science is unlocking the potential of a drug that can slow the progression of degenerative joint disease.
Bryn is developing a new epinephrine nasal spray that improves on the EpiPen in a number of ways. Most importantly, there are no needles.
Bryn is developing a new epinephrine nasal spray that improves on the EpiPen in a number of ways. Most importantly, there are no needles.